Cetera Investment Advisers trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 10.3% during the first quarter, HoldingsChannel reports. The fund owned 80,566 shares of the company’s stock after selling 9,238 shares during the quarter. Cetera Investment Advisers’ holdings in Zoetis were worth $9,524,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC raised its position in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC raised its position in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares during the period. Finally, Glenview Trust co lifted its holdings in Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the period. Institutional investors own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on ZTS. Morgan Stanley decreased their price target on Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup decreased their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $118.33.
Zoetis Stock Down 2.4%
Shares of NYSE:ZTS opened at $76.04 on Friday. The business’s 50 day simple moving average is $77.13 and its two-hundred day simple moving average is $102.66. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market cap of $31.88 billion, a P/E ratio of 12.61, a PEG ratio of 1.22 and a beta of 0.75.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.
Insider Transactions at Zoetis
In related news, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 over the last ninety days. 0.22% of the stock is currently owned by insiders.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
